Last month, Benchmark announced the sale of Benchmark Genetics Ltd and Benchmark Genetics Norway AS to Starfish Bidco AS, a wholly owned subsidiary of Novo Holdings AS, for an enterprise value of up ...

A Sheffield-based aquaculture biotechnology company says it has been through a “transformational” year after selling one of ...

Though M&A deal value and volume both declined in biopharma in 2024 compared to the year prior, PwC analysts still believe ...

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...

Catalent (CTLT) stock rises on reports of imminent $16.5 billion sale to Novo Holdings with FTC approval and EU Commission ...

By far, the largest acquisition of 2024 was Novo Holdings' yet-to-be-closed buyout of manufacturer Catalent at $16.5 billion.

Economic resilience and several strong sector showings boost Nordic dealmaking in 2024, with a healthy M&A pipeline for 2025 - ...

In the U.S., the chorus of opposition against the proposed buyout continues to grow and now includes the CEOs of Roche and ...

This week we discuss the outcome of a motion to drop the subpoena against former IU men’s basketball physician Brad Bomba Sr.

The BIOSECURE Act, which would restrict drugmakers from using key Chinese contract manufacturers, was left out of a defense ...

Catalent, Inc. (“Catalent”) and Novo Holdings A/S (“Novo Holdings”) jointly announced today the unconditional approval granted by the European Commission (EC) for the pending acquisition transaction ...

Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free ...